Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 8/20 | 0.55 |
| ▸ | PLK2 | Q9NYY3 | 8/20 | 0.55 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2052462 | 1.00 | PLK1 (0.55) | PLK1PLK2PLK3 | |
| SCHEMBL1288769 | 0.86 | PLK1 (0.45) | PLK1PLK2PLK3 | |
| SCHEMBL1288767 | 0.86 | PLK1 (0.45) | PLK1PLK2PLK3 | |
| SCHEMBL2689675 | 0.85 | PLK1 (0.45) | PLK1PLK2PLK3 | |
| SCHEMBL2689674 | 0.85 | PLK1 (0.45) | PLK1PLK2PLK3 | |
| SCHEMBL6844754 | 0.79 | PLK1 (0.51) | PLK1PLK2PLK3 | |
| SCHEMBL2050260 | 0.76 | PLK1 (0.56) | PLK1PLK2PLK3 | |
| SCHEMBL2050256 | 0.76 | PLK1 (0.56) | PLK1PLK2PLK3 | |
| SCHEMBL2052447 | 0.75 | PLK1 (0.60) | PLK1PLK2PLK3 | |
| SCHEMBL2048059 | 0.75 | PLK1 (0.60) | PLK1PLK2PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2516441-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK1 1/4885PLK2 22/4885PLK3 101/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK1 1/4885PLK2 22/4885PLK3 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.